Your browser is no longer supported. Please, upgrade your browser.
Settings
MYOK MyoKardia, Inc. daily Stock Chart
MYOK [NASD]
MyoKardia, Inc.
Index- P/E- EPS (ttm)-7.12 Insider Own0.20% Shs Outstand49.88M Perf Week5.98%
Market Cap6.95B Forward P/E- EPS next Y-6.91 Insider Trans-42.99% Shs Float49.28M Perf Month30.34%
Income-334.00M PEG- EPS next Q-1.47 Inst Own- Short Float10.87% Perf Quarter38.38%
Sales- P/S- EPS this Y-249.90% Inst Trans12.08% Short Ratio13.65 Perf Half Y160.51%
Book/sh18.22 P/B7.35 EPS next Y-19.60% ROA-55.80% Target Price137.45 Perf Year161.63%
Cash/sh17.68 P/C7.57 EPS next 5Y50.90% ROE-63.10% 52W Range42.65 - 137.84 Perf YTD83.71%
Dividend- P/FCF- EPS past 5Y-52.00% ROI- 52W High-2.69% Beta1.95
Dividend %- Quick Ratio21.00 Sales past 5Y- Gross Margin- 52W Low214.49% ATR5.64
Employees275 Current Ratio21.00 Sales Q/Q- Oper. Margin- RSI (14)67.92 Volatility3.83% 4.77%
OptionableYes Debt/Eq0.00 EPS Q/Q-53.80% Profit Margin- Rel Volume0.75 Prev Close133.90
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume392.48K Price134.13
Recom1.60 SMA209.70% SMA5023.75% SMA20060.87% Volume292,641 Change0.17%
Sep-20-19Initiated Guggenheim Buy
Oct-01-18Initiated Cantor Fitzgerald Overweight $90
Sep-28-18Initiated Citigroup Buy $90
Sep-10-18Initiated Morgan Stanley Overweight $72
Jul-10-18Initiated BofA/Merrill Buy $71
Jan-18-18Resumed Credit Suisse Outperform $60
Dec-12-17Initiated JP Morgan Overweight $54
Sep-19-17Reiterated Credit Suisse Outperform $45 → $55
Dec-04-15Initiated Wells Fargo Outperform
Nov-23-15Initiated Wedbush Outperform $22
Nov-23-15Initiated Credit Suisse Outperform $18
Sep-09-20 08:00AM  
Sep-08-20 09:52AM  
Sep-02-20 08:00AM  
Aug-29-20 09:30AM  
Aug-11-20 07:35AM  
Aug-10-20 04:05PM  
Aug-05-20 04:05PM  
07:01AM  
Aug-04-20 04:05PM  
Aug-03-20 09:52AM  
08:30AM  
Jul-28-20 08:00AM  
Jul-23-20 04:05PM  
Jul-21-20 07:30AM  
Jul-13-20 05:03PM  
Jul-06-20 08:00AM  
Jun-22-20 08:00AM  
Jun-19-20 08:30AM  
Jun-16-20 08:00AM  
Jun-05-20 11:48AM  
Jun-02-20 11:54PM  
May-16-20 06:51AM  
May-12-20 09:34PM  
01:43PM  
10:09AM  
May-11-20 04:02PM  
10:50AM  
10:49AM  
10:42AM  
07:30AM  
May-06-20 04:05PM  
Apr-07-20 02:16PM  
08:32AM  
Mar-30-20 10:30AM  
Mar-27-20 10:45AM  
Mar-26-20 08:30AM  
Mar-23-20 08:24AM  
Mar-19-20 04:45PM  
Mar-15-20 09:40AM  
Mar-10-20 01:45PM  
Feb-27-20 04:05PM  
08:38AM  
Feb-24-20 08:00AM  
Feb-20-20 08:00AM  
Feb-10-20 05:53PM  
Feb-07-20 12:03PM  
Jan-06-20 08:00AM  
Dec-19-19 09:17AM  
Dec-09-19 02:19PM  
Dec-06-19 11:11PM  
Dec-02-19 02:00PM  
Nov-27-19 08:00AM  
Nov-11-19 07:30AM  
07:30AM  
Nov-06-19 04:05PM  
Nov-04-19 04:44PM  
08:30AM  
Oct-28-19 08:30AM  
Oct-08-19 10:57AM  
Sep-26-19 04:05PM  
Sep-10-19 08:44AM  
Aug-31-19 05:00AM  
Aug-28-19 04:05PM  
04:00PM  
Aug-26-19 08:30AM  
Aug-23-19 09:45AM  
Aug-22-19 12:01PM  
Aug-21-19 08:30AM  
Aug-15-19 08:30AM  
Aug-14-19 10:54AM  
Aug-08-19 01:40PM  
Aug-07-19 08:15PM  
04:05PM  
08:00AM  
Jul-31-19 04:05PM  
Jul-18-19 08:30AM  
Jun-24-19 08:30AM  
Jun-14-19 08:28AM  
Jun-12-19 11:25AM  
May-28-19 08:30AM  
May-10-19 12:34AM  
May-09-19 07:35PM  
06:31PM  
07:46AM  
May-08-19 04:10PM  
May-07-19 04:10PM  
May-02-19 08:00AM  
Apr-30-19 02:52PM  
08:30AM  
Apr-12-19 09:10AM  
Mar-27-19 07:30AM  
Mar-26-19 06:45PM  
07:36AM  
Mar-25-19 04:01PM  
Mar-06-19 08:00AM  
Mar-05-19 10:02PM  
08:48AM  
Mar-04-19 09:42AM  
08:02AM  
Feb-28-19 09:28AM  
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company; and a strategic collaboration and license agreement with Fulcrum Therapeutics, Inc. to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GIANAKAKOS ANASTASIOSPresident and CEOJul 02Sale93.985,000469,90919,122Jul 07 05:39 PM
CRANSTON MARY BDirectorJun 30Option Exercise11.6921,629252,84321,629Jul 01 07:28 PM
CRANSTON MARY BDirectorJun 30Sale96.6021,6292,089,3550Jul 01 07:28 PM
CRANSTON MARY BDirectorJun 29Option Exercise11.693714,337371Jul 01 07:28 PM
CRANSTON MARY BDirectorJun 29Sale98.6837136,6110Jul 01 07:28 PM
GIANAKAKOS ANASTASIOSPresident and CEOJun 02Sale102.845,000514,20824,122Jun 04 04:24 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 18Sale125.0010,0001,250,00029,122May 20 04:55 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 11Sale101.8625,0002,546,47739,122May 13 05:15 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 04Sale58.485,000292,38774,122May 06 07:07 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 30Option Exercise1.5111,50017,328289,582May 04 05:34 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 16Sale55.001,00055,00076,796Apr 20 06:10 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 08Sale50.001,50075,00077,796Apr 10 06:27 PM
Harris Taylor C.Chief Financial OfficerApr 06Sale46.991,30561,3227,438Apr 07 05:42 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 02Sale44.772,500111,91779,296Apr 06 04:06 PM
GIANAKAKOS ANASTASIOSPresident and CEOMar 02Sale64.455,000322,24681,796Mar 04 05:42 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 03Sale69.365,000346,82186,777Feb 05 08:22 PM
Fairey WilliamSee RemarksFeb 01Sale68.042,899197,2485,226Feb 03 08:55 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 14Sale75.395,000376,96591,777Jan 14 08:26 PM
McDowell Robert ScottChief Scientific OfficerJan 06Sale68.452,650181,3955,383Jan 07 07:39 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 06Sale68.4512,687868,43996,777Jan 07 07:39 PM
Harris Taylor C.Chief Financial OfficerJan 06Sale68.451,683115,2034,993Jan 07 07:39 PM
LADD CYNTHIA JGeneral CounselJan 06Sale68.451,849126,5662,851Jan 07 07:36 PM
Bauer JakeChief Business OfficerJan 06Sale68.452,466168,80057,491Jan 07 05:15 PM
Bauer JakeChief Business OfficerJan 03Option Exercise1.5110,00015,10059,957Jan 07 05:15 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 03Sale71.805,000359,008109,464Jan 03 08:18 PM
Bauer JakeChief Business OfficerDec 20Option Exercise11.1517,500195,05062,498Dec 23 09:07 PM
Bauer JakeChief Business OfficerDec 20Sale70.0718,9161,325,42143,582Dec 23 09:07 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 02Sale65.025,000325,09886,514Dec 04 04:26 PM
Bauer JakeChief Business OfficerNov 29Sale65.608,136533,71144,998Dec 02 04:10 PM
Bauer JakeChief Business OfficerNov 27Sale65.1313,096852,97753,134Dec 02 04:10 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 04Sale59.075,000295,36591,514Nov 06 06:33 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 03Sale55.001,00055,00096,470Oct 04 05:27 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 02Sale52.284,000209,11197,470Oct 04 05:27 PM